This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

NattoPharma ASA and Dr Wolz Zell GmbH have entered into a license and marketing agreement giving Dr Wolz access to utilize the MenaQ7® brand and NattoPharma patents in their sales and marketing of vitamin K2.

 

NattoPharma's VP of Sales & Marketing, Siri Stabel Olsen says: "We are very pleased that Dr Wolz see the benefit of vitamin K2 for the consumers. Dr Wolz is a very successful German company distributing high quality products to the dietary supplement market. MenaQ7 will have a high priority in their marketing and sales activities the coming years and several new products containing MenaQ7 will be launched."

 

For more information:

CEO Morten Sundstø

Tel: +47 950 61860